Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVXT in mild to moderate onychomycosis
NCT02933879Phase 2Completed
- Start
- Mar 2016
- Primary completion
- Mar 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NP213 in onychomycosis (3 arms). Primary endpoint: Number of Patients in Each Treatment Group With a Complete Therapeutic Cure at Day 141. Started Mar 2016; status: completed.
02
Drugs
NP213
03
Conditions
onychomycosis
Beyond the preview
Go deeper on NCT02933879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02933879.